{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-031466","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.712597+00:00","generated_at":"2026-05-17T02:41:18.077251+00:00","sec_items":["7.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026","bullets":["Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.","Bir is a seasoned biopharma executive with prior roles at Reata, Geron, Soleno, and Pharmacyclics.","Company plans to initiate first clinical study for simufilam in TSC-related epilepsy in first half of 2026.","Bir eligible for standard non-employee director compensation; no material interests or arrangements disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-031466","json":"https://secwatch.observer/filing/0001437749-25-031466.json","markdown":"https://secwatch.observer/filing/0001437749-25-031466.md","text":"https://secwatch.observer/filing/0001437749-25-031466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/0001437749-25-031466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/sava20251020_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:41:18.077251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}